FIELD: biochemistry.
SUBSTANCE: invention is related to biochemistry, particularly to using monoclonal antibodies to CD44 or its antigen-binding fragment for treating squamous cell carcinoma of the head and the neck (HNSSS) in mammals, where HNSCC differs CD44 expression. Said CD44 antibody can be obtained using the hybridoma, which is deposited in the ATSS under registration number PTA-4621, as well as it can be a chimeric or humanized version.
EFFECT: invention provides effective treatment of HNSCC using nonconjugate ("bare") CD44 antibodies.
12 cl, 15 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| ANTIBODIES FOR TREATMENT OF INFECTION AND DISEASES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE | 2011 |
|
RU2630663C9 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| ANTI-TUMOUR ANTIGEN ANTIBODY AND METHODS OF APPLICATION | 2011 |
|
RU2598711C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
